• Products
  • Preclinical
  • Phase 1/2
  • Phase 3
  • Marketed
  • TPM®/Diclofenac GelPain and inflammation due to muscle, tendon and joint injuries
    Themis Medicare (India + 16 countries*); Novartis (India)
  • TPM®/Oxymorphone PatchModerate to severe chronic pain
    None
  • TPM®/Oxycodone PatchTBD; localized pain conditions
    None
  • TPM®/Tretinoin GelAcne vulgaris
    None
  • TPM®/Propofol InjectionAnesthesia
    Joint R&D partnership with Terumo; Terumo has Japanese rights
  • TPM®/Daptomycin Lyophilized Powder for IV InjectionComplicated skin and skin structure infections (cSSSI)
    Mylan has worldwide marketing rights
  • Several undisclosed TPM®-based products for InjectionTBD
    None

Note: all development phases are not applicable for 505(b)2 regulatory filings in the USA, or similar filings in other jurisdictions
* Armenia, Belarus, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Moldova, Philippines, Rwanda, Sri Lanka, Tanzania, Turkmenistan, Uganda, Ukraine, Uzbekistan and Vietnam